Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm

References

• Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. Helminth infections: the great neglected tropical diseases. J. Clin. Invest.118(4), 1311–1321 (2008).
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Bethony J, Bottazzi ME, Brooker S, Diemert D, Loukas A. New technologies for the control of human hookworm infection. Trends Parasitol.22, 327–331 (2006).
   PubMed Web of Science ®Google Scholar
• Goud GN, Bottazzi ME, Zhan B et al. Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in pichia pastoris and purification of the recombinant protein for use in human clinical trials. Vaccine23(39), 4754–4764 (2005).
   PubMed Web of Science ®Google Scholar
• Loukas A, Bethony JM, Mendez S et al. Vaccination with recombinant aspartic hemoglobinase reduces parasite load and blood loss after hookworm infection in dogs. PLoS Med.2(10), e295 (2005).
   PubMed Web of Science ®Google Scholar
• Loukas A, Bethony J, Brooker S, Hotez P. Hookworm vaccines: past, present, and future. Lancet Infect. Dis.6(11), 733–741 (2006).
   PubMed Web of Science ®Google Scholar
• Xiao S, Zhan B, Xue J et al. The evaluation of recombinant hookworm antigens as vaccines in hamsters (Mesocricetus auratus) challenged with human hookworm, necator americanus. Exp. Parasitol.118(1), 32–40 (2008).
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Roses-Periago M. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination PLoS Negl. Trop. Dis.2 (9), e300, 1–10 (2008).
   Web of Science ®Google Scholar
• Hotez PJ. The giant anteater in the room: Brazil’s neglected tropical diseases problem. PLoS Negl. Trop. Dis.2(1), e177 (2008).
   PubMedGoogle Scholar
• Morel CM, Acharya T, Broun D et al. Health innovation networks to help developing countries address neglected diseases. Science309(5733), 401–404 (2005).
   PubMed Web of Science ®Google Scholar
• Morel CM, Broun D, Dangi A et al. Health innovation in developing countries to address diseases of the poor. Innovation Strategy Today1, 1–15 (2005).
   Google Scholar
• Thorsteinsdottir H, Quach U, Martin DK, Daar AS, Singer PA. Introduction: promoting global health through biotechnology. Nat. Biotechnol.22(Suppl.), DC3–DC7 (2004).
   PubMed Web of Science ®Google Scholar
• Guimaraes R. Health research in Brazil: context and challenges. Rev. Saude Publica40, 3–10 (2006).
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Ferris MT. The antipoverty vaccines. Vaccine24(31–32), 5787–5799 (2006).
   PubMed Web of Science ®Google Scholar
• Marques MB. An overview of health-related industrial biotechnology in latin america and the caribbean. Bull. Pan. Am. Health Organ.30(2), 95–105 (1996).
   PubMedGoogle Scholar
• Salicrup LA, Fedorkova L. Challenges and opportunities for enhancing biotechnology and technology transfer in developing countries. Biotechnol. Adv.24(1), 69–79 (2006).
   PubMed Web of Science ®Google Scholar
• Gardner CA, Acharya T, Yach D. Technological and social innovation: a unifying new paradigm for global health. Health. Aff. (Millwood)26(4), 1052–1061 (2007).
   PubMed Web of Science ®Google Scholar
• Wheeler C, Berkley S. Initial lessons from public–private partnerships in drug and vaccine development. Bull. World Health Organ.79(8), 728–734 (2001).
   PubMed Web of Science ®Google Scholar
• Bottazzi ME, Miles AP, Diemert D, Hotez PJ. An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. Expert Rev. Vaccines5(2), 189–198 (2006).
   PubMed Web of Science ®Google Scholar
• Jadhav S, Datla M, Kreeftenberg H, Hendriks J. The developing countries vaccine manufacturers’ network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine26(13), 1611–1615 (2008).
   PubMed Web of Science ®Google Scholar
• Henriks J, Poeloengan T, Raw I, Martinez LH, El-Abbadi M. Developing country vaccine manufacturers network (DCVMN), 26–27 April 2001, Baudung, Indonesia. Vaccine20, 285–287 (2002).
   Google Scholar
• Milstien JB, Gaule P, Kaddar M. Access to vaccine technologies in developing countries: Brazil and India. Vaccine25(44), 7610–7619 (2007).
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Bethony J, Bottazzi ME, Brooker S, Buss P. Hookworm: “the great infection of mankind”. PLoS Med.2(3), e67 (2005).
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Zhan B, Bethony JM et al. Progress in the development of a recombinant vaccine for human hookworm disease: the human hookworm vaccine initiative. Int. J. Parasitol.33(11), 1245–1258 (2003).
   PubMed Web of Science ®Google Scholar
• Roberts L. Infectious disease. An ill wind, bringing meningitis. Science320(5884), 1710–1715 (2008).
   PubMed Web of Science ®Google Scholar
• Brooke S, Harner-Jay CM, Lasher H, Jacoby E. How public–private partnerships handle intellectual property: the PATH experience. In: In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices. Krattiger A, Mahoney RT, Nelsen L (Eds). MIHR, Oxford, UK and PIPRA, CA USA 1755 (2007).
   Google Scholar
• Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F. Chapter 15: HPV vaccine use in the developing world. Vaccine24(Suppl. 3), S132–S139 (2006).
   Web of Science ®Google Scholar
• Andrus JK, de Quadros CA. Global access to vaccines. In: AIDS Vaccine Development: Challenges and Opportunities. Koff WC, Kahn P, Gust D (Eds). Horizon Press, Norwich, UK 125–132 (2007).
   Google Scholar
• Oehler J. The role of milestones in licensing deals to assure access to health products in developing countries. IP Strategy Today10, 59–70 (2004).
   Google Scholar
• Martins RM, Bensabath G, Arraes LC et al. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem. Inst. Oswaldo Cruz99(8), 865–871 (2004).
   PubMed Web of Science ®Google Scholar
• Rodrigues DG, Kesselring G. Clinical trials in Brazil, facing the challenges. Monitor75–78 (2008).
   Google Scholar
• Serdobova I, Kieny MP. Assembling a global vaccine development pipeline for infectious diseases in the developing world. Am. J. Public Health96(9), 1554–1559 (2006).
   PubMed Web of Science ®Google Scholar
• de Silva NR, Brooker S, Hotez PJ, Montresor A, Engels D, Savioli L. Soil-transmitted helminth infections: updating the global picture. Trends Parasitol.19(12), 547–551 (2003).
   PubMed Web of Science ®Google Scholar
• Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect. Dis.6, 411–425 (2006).
   PubMed Web of Science ®Google Scholar